Humacyte Inc
$ 0.71
3.89%
17 Apr - close price
- Market Cap 151,772,000 USD
- Current Price $ 0.71
- High / Low $ 0.75 / 0.70
- Stock P/E N/A
- Book Value 0.02
- EPS -0.26
- Next Earning Report 2026-05-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.53 %
- ROE -2.50 %
- 52 Week High 2.93
- 52 Week Low 0.55
About
Humacyte Inc (HUMA) is a pioneering biotechnology company dedicated to revolutionizing vascular and regenerative medicine through the development of innovative human acellular vessels (HAVs). Focusing on urgent clinical needs for vascular reconstruction and chronic disease treatment, Humacyte provides off-the-shelf solutions designed to improve patient outcomes and lower healthcare costs. With its advanced technology platform, the company is poised to drive significant advancements in transplantation and tissue engineering, positioning itself as a leader in the evolving landscape of medical therapies.
Analyst Target Price
$5.10
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-26 | 2025-11-12 | 2025-08-11 | 2025-05-08 | 2025-03-20 | 2024-11-07 | 2024-08-13 | 2024-05-10 | 2024-03-22 | 2023-11-09 | 2023-08-14 | 2023-05-12 |
| Reported EPS | -0.188 | -0.11 | -0.24 | -0.0804 | -0.2091 | -0.33 | -0.48 | -0.29 | -0.24 | -0.25 | -0.22 | -0.36 |
| Estimated EPS | -0.1284 | -0.16 | -0.16 | -0.22 | -0.255 | -0.25 | -0.24 | -0.22 | -0.24 | -0.25 | -0.22 | -0.21 |
| Surprise | -0.0596 | 0.05 | -0.08 | 0.1396 | 0.0459 | -0.08 | -0.24 | -0.07 | 0 | 0 | 0 | -0.15 |
| Surprise Percentage | -46.4174% | 31.25% | -50% | 63.4545% | 18% | -32% | -100% | -31.8182% | 0% | 0% | 0% | -71.4286% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-12 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.1 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: HUMA
2026-04-15 13:09:35
DelveInsight's "Peripheral Artery Disease Pipeline Insight, 2026" report provides a comprehensive assessment of over 20 key companies developing more than 22 treatment therapies for Peripheral Artery Disease (PAD). The report details the clinical development scenario, growth prospects, mechanisms of action, routes of administration, and regulatory approvals for these therapies. Key companies like Ixaka Ltd, Hemostemix Inc., Caladrius Biosciences, Humacyte, Inc., Novo Nordisk, and Helixmith are actively involved in developing emerging therapies such as REX-001, ACP-01, Honedra, Human Acellular Vessel (HAV), Semaglutide, and VM202.
2026-04-13 18:09:57
Kahn Swick & Foti, LLC has launched an investigation into Humacyte, Inc. and its officers and directors over alleged failures to disclose material information to shareholders. The probe follows an FDA Form 483 citing manufacturing violations at Humacyte's Durham facility and a delay in the FDA's review of the company's Biologic License Application. The investigation will determine if Humacyte's leadership breached fiduciary duties or violated laws, potentially impacting the company's operations and stock price.
2026-04-11 17:10:05
Humacyte (NASDAQ:HUMA) has been downgraded by Wall Street Zen from a "sell" to a "strong sell" rating, despite MarketBeat showing a consensus "Moderate Buy" with an average price target of $7.71. The biotechnology company, trading around $0.65 with a $144M market cap, faced mixed analyst ratings following its latest quarterly report, which met EPS estimates but missed revenue expectations and showed negative margins. Analysts project a -$1.27 EPS for the current year, indicating continued financial challenges.
2026-04-10 03:08:53
This article reports that Humacyte's (HUMA) price target has been significantly decreased by 31.82%, bringing it down to $5.46. This change reflects a notable adjustment in the outlook for the company's stock by analysts.
2026-04-10 03:08:53
Halper Sadeh LLC, an investor rights law firm, is investigating whether officers and directors of Humacyte, Inc. (NASDAQ: HUMA) breached their fiduciary duties to shareholders. The firm encourages long-term shareholders of Humacyte to contact them to discuss potential legal options, including corporate governance reforms or the return of funds to the company.
2026-04-09 20:39:04
Halper Sadeh LLC, an investor rights law firm, is investigating whether officers and directors of Humacyte, Inc. (NASDAQ: HUMA) breached their fiduciary duties to shareholders. The firm encourages current long-term shareholders to contact them to discuss potential legal rights and options, including seeking corporate governance reforms or the return of funds to the company. The investigation focuses on holding the company accountable and enhancing shareholder value through improved policies and oversight.
